SynthesisInternational urology and nephrology2025
A meta-analysis of perioperative, oncological, and functional outcomes of robot-assisted partial nephrectomy for completely endophytic and hilar lesions.
Synthesis in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- On-Clamp Versus Off-Clamp Robot-Assisted Partial Nephrectomy for Localized Renal Tumors: A Retrospective Single-Center Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundThis study aims to compare the perioperative, functional, and oncological outcomes of robot-assisted partial nephrectomy in complex renal masses (CRM) with non-CRM tumors.
methodsA systematic literature review was conducted in PubMed, Embase, Web of Science, and Cochrane Library databases, following the PRISMA guidelines. The studies comparing RAPN outcomes between complex renal masses (CRM), specifically completely endophytic and hilar renal tumors, versus non-complex renal masses (non-CRM), which include non-endophytic, and non-hilar renal tumors.
resultsTwelve studies involving 8126 patients were analyzed. The results revealed CRM group increased operative time (Mean Difference [MD]: 14.35 min; 95% CI: 5.14-23.55; p = 0.002), higher blood loss (MD: 20.42 mL; 95% CI: 0.83-40.02; p = 0.041), and greater decline in estimated glomerular filtration rate (eGFR) (MD: 2.19 mL/min/1.73 m
conclusionsRAPN for CRM is associated with longer operative times, increased blood loss, greater decline in eGFR, and higher rates of major complications. However, oncological outcomes (PSM and local recurrence rates) are comparable to those for non-CRM. These findings suggest that RAPN remains a feasible option for treating CRM in experienced centers, provided that careful patient selection and preoperative planning are followed.
Indexed as
Identifiers
39994145What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.